Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P25-DIV3W peptide + CD44 siRNA
- Development stage
- Preclinical
- Lead developer
- Clemson University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
P25-DIV3W peptide + CD44 siRNA is a preclinical peptide-siRNA nanoparticle complex designed for the targeted treatment of HER2-positive (HER2+) breast cancer. Developed at Clemson University, the system employs a tandem peptide (P25-DIV3W) as a non-viral delivery vehicle. The P25 component serves as a targeting ligand that binds specifically to the HER2 receptor, while the DIV3W component is a fusogenic peptide that promotes endosomal escape, ensuring the intracellular delivery of the siRNA cargo. The therapeutic payload consists of siRNA targeting CD44, a cell surface glycoprotein associated with cancer stemness and tumor progression. By silencing CD44 expression, the complex significantly reduces cell viability and induces apoptosis in HER2-overexpressing cancer cells while sparing normal breast epithelial cells.
- Other names
- P25-DIV3W-siCD44P-25-DIV3W-siCD44P 25-DIV3W-siCD44P25-DIV3W/siCD44
02
Targets
CD44 (CD44 antigen)BMP (Bone morphogenetic protein family)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on P25-DIV3W peptide + CD44 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P25-DIV3W peptide + CD44 siRNA.